NCT06582212Recruiting
Enabling Women With Parkinson's Disease to Identify and Better Manage Hormonal Triggers of Parkinsonian Symptoms
Enabling Women With Parkinson's Disease to Identify and Better Manage Hormonal Triggers
Source: ClinicalTrials.gov · Last updated 2 Oct 2026
Brief summary (registry, in English)
Forty percent of people living worldwide with Parkinson's disease (PD) are women. Twenty percent of patients have PD onset under the age of 60 years, a time when women may encounter significant caregiving responsibilities along with occupational and other competing demands. Studies with surveys of women with PD (WwPD) have reported worsening of PDrelated symptoms especially in the week prior and the week of menses. However, prospective evidence is scarce and clinical guidelines to manage this issue do not exist. As a result, care is either non-existent or fragmented. The investigators propose a French multicentre prospective pilot study to capture changes in PD symptoms in relation to the stages of the menstrual cycle aiming at reducing hormonal related worsening in PD symptoms through neurologist intervention and/or patient selfmanagement. Digital technology will remotely enable patient reported outcome (PRO) tracking through the My Moves Matter app changes in PD symptoms during several months. This information will then help neurologists to customize treatment. Changes in motor symptoms will also be highlighted by tracking through the use of a wearable device (PDMonitor) to objectively detect motor changes together with the app. This will further support the reliability of the app. This study will provide evidence for the impact of the menstrual cycle on PD and help neurologists and patients to better manage PD symptoms related to these hormonal changes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 24 Jun 2024
- Start date
- 12 Mar 2025
- Primary completion date
- 12 Mar 2027
- Lead sponsor
- University Hospital, Grenoble
- Diseases
- Parkinson disease
- NCT number
- NCT06582212
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 12 Mar 2025 to the primary completion date, 12 Mar 2027
- 4 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any condition that, in the opinion of the investigator, will preclude the participant from successfully or safely completing study procedures (i.e., dementia, severe depression, etc.)
Other
- Post-menopausal women with PD
- People not able to give an informed consent.
Who the study is looking for
- Non-menopausal women
- Diagnosis of PD according to the MDS criteria onset of PD symptoms since at least two years before inclusion
- Age 18-56 years
- On stable medication regimen for PD for at least two months without foreseen need to modify it within the next three months
- With and without OCP or intrauterine devices (IUD
Age in the registry: 18 years to 56 years · Sex: Female · Does not accept healthy volunteers
Sites (4)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Grenoble Alpes Coordinator of this site? Confirm its status | Grenoble | France | Recruiting |
| CHU Nantes Hôpital Laennec Coordinator of this site? Confirm its status | Nantes | France | Recruiting |
| CHU Rennes -Site Pontchaillou Coordinator of this site? Confirm its status | Rennes | France | Recruiting |
| CHU Toulouse Coordinator of this site? Confirm its status | Toulouse | France | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.